Loading clinical trials...
Loading clinical trials...
A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable Gastric/Esophagogastric Junction Cancer.
Conditions
Interventions
ASKB589 +CAPOX+Sintilimab/Tislelizumab
Locations
1
China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Start Date
February 21, 2023
Primary Completion Date
October 31, 2025
Completion Date
February 10, 2026
Last Updated
September 10, 2025
NCT06921928
NCT06257264
NCT06427941
NCT07537348
NCT06253871
NCT06464978
Lead Sponsor
AskGene Pharma, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions